Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicergoline for post-stroke vascular cognitive impairment without dementia
ChiCTR1900026538Phase 4Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicergoline in vascular cognitive disorder (VCD) (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Change from baseline in VaDAS-Cog score at week 24. Started Dec 2019; status: recruiting.
02
Drugs
nicergoline
03
Conditions
vascular cognitive disorder (VCD)
Beyond the preview
Go deeper on ChiCTR1900026538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026538.